DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more
Market Cap & Net Worth: DexCom Inc (DXCM)
DexCom Inc (NASDAQ:DXCM) has a market capitalization of $25.91 Billion ($25.91 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #779 globally and #612 in its home market, demonstrating a -2.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DexCom Inc's stock price $67.32 by its total outstanding shares 384864842 (384.86 Million).
DexCom Inc Market Cap History: 2015 to 2026
DexCom Inc's market capitalization history from 2015 to 2026. Data shows growth from $7.88 Billion to $25.91 Billion (11.93% CAGR).
Index Memberships
DexCom Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P 500 Index
GSPC
|
$53.17 Trillion | 0.06% | #305 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 1.15% | #14 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.08% | #111 of 3165 |
|
Nasdaq 100
NDX
|
$28.06 Trillion | 0.09% | #86 of 101 |
Weight: DexCom Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
DexCom Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DexCom Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.48x
DexCom Inc's market cap is 5.48 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
30.54x
DexCom Inc's market cap is 30.54 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.74 Billion | $573.30 Million | -$65.60 Million | 10.02x | N/A |
| 2017 | $5.52 Billion | $718.50 Million | -$50.20 Million | 7.69x | N/A |
| 2018 | $11.53 Billion | $1.03 Billion | -$127.10 Million | 11.17x | N/A |
| 2019 | $21.05 Billion | $1.48 Billion | $101.10 Million | 14.26x | 208.17x |
| 2020 | $35.57 Billion | $1.93 Billion | $493.60 Million | 18.46x | 72.07x |
| 2021 | $51.66 Billion | $2.45 Billion | $216.90 Million | 21.10x | 238.19x |
| 2022 | $43.58 Billion | $2.91 Billion | $341.20 Million | 14.98x | 127.73x |
| 2023 | $47.76 Billion | $3.62 Billion | $541.50 Million | 13.18x | 88.20x |
| 2024 | $29.93 Billion | $4.03 Billion | $576.20 Million | 7.42x | 51.95x |
| 2025 | $25.54 Billion | $4.66 Billion | $836.30 Million | 5.48x | 30.54x |
Competitor Companies of DXCM by Market Capitalization
Companies near DexCom Inc in the global market cap rankings as of March 18, 2026.
Key companies related to DexCom Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
DexCom Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, DexCom Inc's market cap moved from $7.88 Billion to $ 25.91 Billion, with a yearly change of 11.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.91 Billion | +1.43% |
| 2025 | $25.54 Billion | -14.66% |
| 2024 | $29.93 Billion | -37.33% |
| 2023 | $47.76 Billion | +9.58% |
| 2022 | $43.58 Billion | -15.64% |
| 2021 | $51.66 Billion | +45.23% |
| 2020 | $35.57 Billion | +69.02% |
| 2019 | $21.05 Billion | +82.59% |
| 2018 | $11.53 Billion | +108.75% |
| 2017 | $5.52 Billion | -3.87% |
| 2016 | $5.74 Billion | -27.11% |
| 2015 | $7.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of DexCom Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.91 Billion USD |
| MoneyControl | $25.91 Billion USD |
| MarketWatch | $25.91 Billion USD |
| marketcap.company | $25.91 Billion USD |
| Reuters | $25.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.